Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.73 |
| ▸ | RXFP1 | Q9HBX9 | 11/20 | 0.67 |
| ▸ | TP53 | P04637 | 6/20 | 0.67 |
| ▸ | NEDD4 | P46934 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17141965 | 0.90 | LMNA (0.64) | LMNARXFP1TP53NEDD4MAPT | |
| SCHEMBL18996019 | 0.85 | NEDD4 (0.86) | LMNARXFP1TP53NEDD4MAPT | |
| SCHEMBL17141924 | 0.83 | LMNA (0.59) | LMNARXFP1TP53NEDD4MAPT | |
| SCHEMBL17141947 | 0.81 | RXFP1 (0.57) | LMNARXFP1TP53NEDD4MAPT | |
| SCHEMBL17141990 | 0.80 | NEDD4 (1.00) | LMNARXFP1NEDD4MAPT | |
| SCHEMBL17141988 | 0.76 | NEDD4 (0.83) | LMNARXFP1TP53NEDD4MAPT | |
| SCHEMBL18996018 | 0.73 | NEDD4 (0.81) | LMNATP53NEDD4MAPT | |
| SCHEMBL17141921 | 0.71 | NEDD4 (0.71) | LMNARXFP1TP53NEDD4MAPT | |
| SCHEMBL17141933 | 0.70 | NEDD4 (0.79) | LMNARXFP1NEDD4MAPT | |
| SCHEMBL17141981 | 0.69 | NEDD4 (0.76) | LMNARXFP1TP53NEDD4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174678-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | Rhe Trustees of The University of Pennsylvania | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174678-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | ZC3HAV1, MAVS, ZC3HAV1L | LMNA 2215/4885RXFP1 1870/4885TP53 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.